These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10169536)

  • 1. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system.
    Weintraub WS; Warner CD; Mauldin PD; Becker ER; Gomes D; Cook J; Kosinski A; Boccuzzi S
    Am J Manag Care; 1997 May; 3(5):743-9. PubMed ID: 10169536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in outpatient mental health service utilization under capitation.
    Chou AF; Wallace N; Bloom JR; Hu TW
    J Ment Health Policy Econ; 2005 Mar; 8(1):3-14. PubMed ID: 15870481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic effects of coronary restenosis after percutaneous coronary intervention in a managed care population.
    Clark MA; Bakhai A; Pelletier EM; Cohen DJ
    Manag Care; 2005 Apr; 14(4):42-4, 46-51. PubMed ID: 15898211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of managed fee-for-service and direct reimbursement.
    van der Wal CJ; Smithwick CL
    J Am Coll Dent; 1997; 64(3):28-36. PubMed ID: 9420385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer cost savings with endometrial ablation therapy.
    London R; Holzman M; Rubin D; Moffitt B
    Am J Manag Care; 1999 Jul; 5(7):889-97. PubMed ID: 10557409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example.
    Schwenkglenks M; Preiswerk G; Lehner R; Weber F; Szucs TD
    J Epidemiol Community Health; 2006 Jan; 60(1):24-30. PubMed ID: 16361451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical economic considerations of coronary stenting.
    Szucs TD
    Schweiz Med Wochenschr; 1999 Nov; 129(45):1701-11. PubMed ID: 10595380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of coronary angioplasty procedures in Poland].
    Gasior M; Gierlotka M; Gasior U; Chodór P; Lekston A; Klosa Z; Balcarek J; Kalarus Z; Poloński L; Zembala M
    Kardiol Pol; 2004 Jul; 61(7):42-7; discussion 48. PubMed ID: 15338017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing paradigms in medical payment.
    Tabbush V; Swanson G
    Arch Intern Med; 1996 Feb; 156(4):357-60. PubMed ID: 8607720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of medical group practice and physician payment methods on costs of care.
    Kralewski JE; Rich EC; Feldman R; Dowd BE; Bernhardt T; Johnson C; Gold W
    Health Serv Res; 2000 Aug; 35(3):591-613. PubMed ID: 10966087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicaid managed care and the distribution of societal costs for persons with severe mental illness.
    Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA
    Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of recent US cost estimates of revascularization.
    Nagle PC; Smith AW
    Am J Manag Care; 2004 Oct; 10(11 Suppl):S370-6. PubMed ID: 15603246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.
    Hlatky MA; Boothroyd DB; Melsop KA; Brooks MM; Mark DB; Pitt B; Reeder GS; Rogers WJ; Ryan TJ; Whitlow PL; Wiens RD
    Circulation; 2004 Oct; 110(14):1960-6. PubMed ID: 15451795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensuring adequate payment for the use of new technology.
    Kaden RJ
    Healthc Financ Manage; 1998 Feb; 52(2):46-52. PubMed ID: 10176449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs in check, but competition will erode capitation margins.
    Capitation Rates Data; 1998 Mar; 3(3):34-6. PubMed ID: 10345859
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience.
    Reynolds MR; Neil N; Ho KK; Berezin R; Cosgrove RS; Lager RA; Sirois C; Johnson RG; Cohen DJ
    Am Heart J; 2003 Feb; 145(2):334-42. PubMed ID: 12595853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.